Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2021.717 | In-hospital initiation of empagliflozin for the treatment of new-onset acute heart failure regardless of ejection fraction: A Pilot Study |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2023.362 | A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.502 | Development of Fluorescence Probes and Nanomaterial for Plaque and Thrombosis Imaging in Patients | Prof. YAN Bryan Ping Yen |
| 2022.501 | The effect of early inpatient initiation of Dapagliflozin on the Health-related Quality of Life of patients with heart failure with all range of Ejection Fraction: a Local Registry | Prof. YAN Bryan Ping Yen |
| 2022.065 | Real World Effectiveness of Evolocumab among Chinese Patients in Hong Kong | Prof. YAN Bryan Ping Yen |
| 2022.573 | Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Willingness to Follow Recommendations for Cardiovascular Prevention | Prof. YAN Bryan Ping Yen |
| 2022.497 | In-hospital initiation of Angiotensin–Neprilysin Inhibition for the treatment of acute heart failure regardless of ejection fraction: An open labelled randomized study | Prof. YAN Bryan Ping Yen |
| 2022.449 | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.409 | Validation of Pulse Sensors for Cardiovascular Disease Management |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2022.335 | Evaluation of the Relationship Between Arterial Stiffness and Coronary Artery Disease by Stroke-Volume-Allocation |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2022.287 | Validation of a novel device for screening patients with atrial fibrillation / arrhythmia | Prof. YAN Bryan Ping Yen |
| 2023.464 | Time-trend analysis of clinical characteristic and outcomes in patients with unprotected left main coronary artery disease treated with PCI over a 10-year period from year 2010 till year 2020. | Prof. YAN Bryan Ping Yen |
| 2022.162 | A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2022.164 | A Study on Outcomes of Surgical and Percutaneous Left Atrial Appendage Closure |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2023.194 | A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Below-the-Knee (BTK) Atherosclerotic Disease in Patients With Chronic Limb Threatening Ischemia (CLTI) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2021.637 | Drug-Coated Balloon for the Treatment of De Novo and Restenotic Coronary Artery Lesion: a prospective observational study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2023.041 | A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT) |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2019.021 | Activation Pattern and Acute Hemodynamics of His and Left Bundle Pacing | Prof. YAN Bryan Ping Yen |
| 2019.571 | Gaps In Awareness of Peripheral Arterial Disease in Hong Kong: A Cross Sectional Study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.442 | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2020.080 | A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2018.393 | Validation of a cuffless blood pressure device for 24-hours ambulatory blood pressure monitoring |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.215 | Electrical Activation Mapping Guided Cardiac Resynchronization Therapy for Nonresponders | Prof. YAN Bryan Ping Yen |
| 2018.382 | ILUMIEN IV: OPTIMAL PCI OPtical Coherence Tomography (OCT) Guided Coronary Stent IMplantation Compared to Angiography: a Multicenter Randomized TriaL in PCI |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.653 | In-Depth Analyses of 12-lead ECG P-wave Indices Using Machine Learning to Predict Atrial Fibrillation and Cardiovascular Events |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.214 | XIENCE 28 Global Study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2020.082 | A Non-randomized, Clinical Registry of the DynamX Novolimus Eluting Coronary Bioadaptor System in the Treatment of Patients with De Novo Native Coronary Artery Lesions |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2019.357 | Prolonged Ambulatory Heart Rate Variability Monitoring to Predict Major Adverse Cardiac Events in High-risk Patients with Cardiovascular Diseases |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2020.448 | Rationale and Design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): A Randomized, Open-label study |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2018.304 | Achievement of cardiovascular risk factor goals and target levels in patients at very-high and high cardiovascular risk in Hong Kong |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2020.154 | BIOFLOW-DAPT: BIOTRONIK – A Prospective, Randomized, Multi-center Study to Assess the SaFety of the Orsiro Mission Stent compared to the ResoLute Onyx Stent in Subjects at High Risk for Bleeding in combination With 1-month Dual AntiPlatelet Therapy |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2019.346 | HD Mapping Observational Study |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2018.299 | Lipid management status of patients with ischemic stroke (IS) in Hong Kong | Prof. YAN Bryan Ping Yen |
| 2019.004 | Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2024.251 | BIOTRONIK – Safety and Clinical Performance of the Drug Eluting Resorbable Coronary MAGnesium Scaffold System (Freesolve) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A randomized controlled trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.339 | Investigations of cardiotoxicity in cancer survivors | Prof. YAN Bryan Ping Yen |
| 2024.468 | AI-Based Intima-Media Thickness Measurement for Cardiovascular Risk Assessment |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.212 | Retrospective Database Study for Treatment Patterns of Lipid-lowering Therapy in Patients with Hypercholesterolemia or Mixed Dyslipidemia in Hong Kong, South Korea, and Taiwan (READY Study) |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.156 | A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2024.152 | Rationale and design of Dabigatran for Mitral Stenosis Atrial Fibrillation Trial |
Prof. YAN Bryan Ping Yen 甄秉言 |
| 2014.210 | Randomized controlled trial and cost-effectiveness analysis of targeted rapid screening for atrial fibrillation using a handheld single-lead ECG device with automated diagnostics and tailored stroke prevention strategy for screen-detected patients | Prof. YAN Bryan Ping Yen |
| 2013.420 | Transcatheter Renal Denervation with an over-the-wire balloon based technology for Patiemts with Resistant Hypertension | Prof. YAN Bryan Ping Yen |
| 2013.586 | GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (Phase II/III) | Prof. YAN Bryan Ping Yen |
| 2012.561 | Novel Treatment of Intermittent Claudication in Patients with Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule | Prof. YAN Bryan Ping Yen |
| 2014.332 | A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting. (RE-DUAL PCI) | Prof. YAN Bryan Ping Yen |
| 2011.178 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Prof. YAN Bryan Ping Yen |
| 2012.481 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome | Prof. YAN Bryan Ping Yen |
| 2013.658 | A PHASE 3 DOUNLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDMIA AT RISK OF CARDIOVASCULAR EVENTS | Prof. YAN Bryan Ping Yen |
| 2009.542 | Impact of unrecognized peripheral arterial disease and additional prognostic value of ankle-brachial index to risk-stratify patients at high cardiovascular risk undergoing coronary angiography or intervention | Prof. YAN Bryan Ping Yen |
| 2009.543 | Patients at High Cardiovascular Risk Lack Awareness of the Importance of Risk Factor Modification and the Dire Consequences Associated with Peripheral Artery Disease : A cross sectional cohort study | Prof. YAN Bryan Ping Yen |
Page 246 of 262.